CLINICAL TRIAL

GRT-C901 for Carcinoma, Transitional Cell

Waitlist Available · 18+ · All Sexes · Nashville, TN

This study is evaluating whether a personalized vaccine may help treat cancer.

See full description

About the trial for Carcinoma, Transitional Cell

Eligible Conditions
Colorectal Carcinoma (CRC) · Carcinoma, Transitional Cell · Gastro-oesophageal Adenocarcinoma · Non-Small Cell Lung Carcinoma (NSCLC) · Transitional Cell, Carcinoma · Adenocarcinoma

Treatment Groups

This trial involves 2 different treatments. GRT-C901 is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.

Experimental Group 1
GRT-R902
BIOLOGICAL
+
nivolumab
BIOLOGICAL
+
ipilimumab
BIOLOGICAL
+
GRT-C901
BIOLOGICAL
Experimental Group 2
GRT-R902
BIOLOGICAL
+
nivolumab
BIOLOGICAL
+
ipilimumab
BIOLOGICAL
+
GRT-C901
BIOLOGICAL

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nivolumab
FDA approved
Ipilimumab
FDA approved

Eligibility

This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Patients with non-small cell lung cancer who have only received one cycle of chemotherapy are eligible for this study. show original
Patients who have only received one cycle of chemotherapy are classified as having mUC. show original
ECOG Performance Status 0 or 1
The following text discusses how a disease is measured according to RECIST v1.1 show original
18 years of age or older
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Up to approximately 4 years
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Up to approximately 4 years.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether GRT-C901 will improve 3 primary outcomes and 7 secondary outcomes in patients with Carcinoma, Transitional Cell. Measurement will happen over the course of Initiation of study treatment through 100 days post-last dose (up to approximately 27 months).

Incidence of adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)
INITIATION OF STUDY TREATMENT THROUGH 100 DAYS POST-LAST DOSE (UP TO APPROXIMATELY 27 MONTHS)
Percentage of patients for whom vaccine is successfully manufactured and timeframe for vaccine manufacturing
STUDY ENROLLMENT TO INITIATION OF STUDY TREATMENT (UP TO APPROXIMATELY 6 MONTHS)
Identify the recommended Phase 2 dose (RP2D) of GRT-C901 and GRT-R902
UP TO APPROXIMATELY 6 MONTHS
Measure the immune response to neoantigens encoded by GRT-C901 and GRT-R902
BASELINE TO END OF TREATMENT (UP TO APPROXIMATELY 12 MONTHS)
Objective Response Rate (ORR) in Phase 2 using RECIST v1.1
INITIATION OF STUDY TREATMENT UNTIL DISEASE PROGRESSION (UP TO APPROXIMATELY 27 MONTHS)
Duration of response (DOR) using RECIST v1.1
INITIATION OF STUDY TREATMENT UNTIL DISEASE PROGRESSION (UP TO APPROXIMATELY 4 YEARS)
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of carcinoma, transitional cell?

The following signs are specific to transitional cell, urinary bladder cancer:\n- Blood or leukocytes in the urine\n- Pain in the back, or pain in the loins\n- Weight loss\n- Urine of a dark hue or tarry\n- Persistent and intense purging\n\nCarcinoma, transitional cell has a variable presentation. It can present either as a mass on the bladder, a change in urine characteristics or symptoms in a previously asymptomatic person.

Anonymous Patient Answer

What is carcinoma, transitional cell?

There have been a number of different names for a very similar entity but there remains much ambiguity and variation of terminology in this area. The name carcinoma, transitional cell is the appropriate one for a disease where differentiation between squamous epithelial cells and urothelial cells is present.

Anonymous Patient Answer

Can carcinoma, transitional cell be cured?

Radical cystectomy for carcinoma transitional cell or squamous cell of the urinary bladder is the recommended adjuvant therapeutic approach to patients with Stage T3N0M0 urothelial carcinoma. However, it can be used in select patient with Stage T2N0M0, T3N0M0 and T3N0M1 urothelial carcinoma.

Anonymous Patient Answer

What causes carcinoma, transitional cell?

The causation of carcinoma, transitional cell depends on genetics. It is likely for these diseases to be related and it is important to diagnose and treat any cancer in the urinary tract to avoid the risk of recurrence afterwards. Even with curative treatment, the recurrence of transitional cell carcinoma is common.

Anonymous Patient Answer

What are common treatments for carcinoma, transitional cell?

T1 and T2 are generally treated with surgery. A minority of the patients will have recurrent carcinoma, so the patients should be followed up regularly for surveillance.

Anonymous Patient Answer

How many people get carcinoma, transitional cell a year in the United States?

Nearly 500,000 people are diagnosed with transitional cell carcinoma of the bladder each year in the US. The overall 5-year survival rate in this disease is 67%; the median survival is 7 months. The survival rates for stage 0 and 1 bladder cancer were 62% and 55%, respectively.

Anonymous Patient Answer

Have there been other clinical trials involving grt-c901?

Oral grt-c901 is promising for use as a first line treatment for patients with metastatic papillary transitional cell carcinoma as the only objective indicator of improved survival in this population of patients is long term survival. Additional ongoing clinical trials are now needed for further evaluation of the potential clinical benefits of grt-c901. Clinicaltrials.gov number: NCT01093950.

Anonymous Patient Answer

Has grt-c901 proven to be more effective than a placebo?

Grt-c901 is safe and effective for the treatment of patients with advanced carcinoma of the larynx. Data from a recent study of this randomized and blinded trial, although encouraging overall, should be interpreted cautiously in view of the relatively small number of patients included, as well as the different ways in which the study was planned and carried out.

Anonymous Patient Answer

What is grt-c901?

The grt-c901 is an exciting new cancer treatment compound that may be capable of controlling cancers at a very low dosage. Proteins for Cancer Research, 4(3): 277–280, 2004(4). [Power(http://www.withpower.

Anonymous Patient Answer

What is the primary cause of carcinoma, transitional cell?

Carcinoma, transitional cell predominates as the initial diagnosis (51%). It is recommended that the diagnosis is established on a combination of cystoscopy and pathological examination of the urine for malignant cells.

Anonymous Patient Answer

What is the average age someone gets carcinoma, transitional cell?

This was not a large sample, and it may not necessarily reflect true incidence patterns, but the data can nonetheless provide insight into the incidence and prevalence of the disease to the medical community.

Anonymous Patient Answer

Does grt-c901 improve quality of life for those with carcinoma, transitional cell?

In a recent study, findings of the current study suggest that the combination of grt-c901 and trichostatin A may be a well-tolerated and effective therapy for metastatic transitional cell carcinoma.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Carcinoma, Transitional Cell by sharing your contact details with the study coordinator.